The five-year, €25 million project will use firm’s platforms for earlier identification of xenobiotic adverse effects.
GeneGo will help the Netherlands Toxicogenomics Center (NTC) in its integrated systems toxicology approach to risk assessment. This five-year, €25 million, multiparty program is aimed at developing omics-based screens for the evaluation of chemical safety in humans and the possible replacment or reduction of animal experiments.
The NTC will use GeneGo’s MetaCore and MetaDrug systems biology data analysis platform to identify the key biological functions and pathways contributing to the adverse effects of xenobiotic exposure. They will coordinate, visualize, and interpret chemical, metabolomic, proteomic, and gene expression data.
GeneGo will work within the bioinformatics group of the NTC to build predictive models using its Functional Descriptor technology. The goal is to identify as early as possible adverse effects in animals from short-term in vivo experiments or during in vitro investigations.